- Letter regarding “Risk factors in nonalcoholic fatty liver disease”
-
Pratap A, More U, Phalak P, Deshmukh A
- KMID: 2546391
- Clin Mol Hepatol.
- 2023 Oct;29(4):1046-1047.
- doi: 10.3350/cmh.2023.0268
-
- CITED
-
- Close
- SHARE
-
- Close
- Adding to the confusion in more than just the name
-
George J
- KMID: 2546382
- Clin Mol Hepatol.
- 2023 Oct;29(4):973-976.
- doi: 10.3350/cmh.2023.0367
-
- CITED
-
- Close
- SHARE
-
- Close
- Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
-
Kim HC
- KMID: 2546385
- Clin Mol Hepatol.
- 2023 Oct;29(4):984-986.
- doi: 10.3350/cmh.2023.0275
-
- CITED
-
- Close
- SHARE
-
- Close
- Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
-
Yoon SM
- KMID: 2546383
- Clin Mol Hepatol.
- 2023 Oct;29(4):977-979.
- doi: 10.3350/cmh.2023.0336
-
- CITED
-
- Close
- SHARE
-
- Close
- The role of the hepatic autonomic nervous system
-
Luo Q, Liu P, Dong Y, Qin T
- KMID: 2546394
- Clin Mol Hepatol.
- 2023 Oct;29(4):1052-1055.
- doi: 10.3350/cmh.2023.0244
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”
-
Yoon EL, Jun DW
- KMID: 2546393
- Clin Mol Hepatol.
- 2023 Oct;29(4):1050-1051.
- doi: 10.3350/cmh.2023.0310
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Evidence-based hyponatremia management in liver disease”
-
Theodorou DJ, Theodorou SJ, Mitselos IV
- KMID: 2546390
- Clin Mol Hepatol.
- 2023 Oct;29(4):1043-1045.
- doi: 10.3350/cmh.2023.0204
-
- CITED
-
- Close
- SHARE
-
- Close
- From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
-
Yeh ML, Yu ML
- KMID: 2546381
- Clin Mol Hepatol.
- 2023 Oct;29(4):969-972.
- doi: 10.3350/cmh.2023.0359
-
- CITED
-
- Close
- SHARE
-
- Close
- Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
-
Han E, Lee Yh
- KMID: 2546384
- Clin Mol Hepatol.
- 2023 Oct;29(4):980-983.
- doi: 10.3350/cmh.2023.0250
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
-
Ryu JY, Baek SH, Kim S
- KMID: 2546392
- Clin Mol Hepatol.
- 2023 Oct;29(4):1048-1049.
- doi: 10.3350/cmh.2023.0261
-
- CITED
-
- Close
- SHARE
-
- Close
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
-
Kim GA, Moon JH, Kim W
- KMID: 2546372
- Clin Mol Hepatol.
- 2023 Oct;29(4):831-843.
- doi: 10.3350/cmh.2023.0277
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word ‘fatty.’ Three pan-national liver... -
- CITED
-
- Close
- SHARE
-
- Close
- Waiting for the changes after the adoption of steatotic liver disease
-
Yoon EL, Jun DW
- KMID: 2546373
- Clin Mol Hepatol.
- 2023 Oct;29(4):844-850.
- doi: 10.3350/cmh.2023.0291
Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys,... -
- CITED
-
- Close
- SHARE
-
- Close
- Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma
-
Lee SU, Kim TH
- KMID: 2546380
- Clin Mol Hepatol.
- 2023 Oct;29(4):958-968.
- doi: 10.3350/cmh.2023.0274
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, and external beam radiation therapy has emerged as a promising approach for managing HCC. Proton beam therapy (PBT) offers dosimetric... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
-
Inoue T, Watanabe T, Tanaka Y
- KMID: 2546374
- Clin Mol Hepatol.
- 2023 Oct;29(4):851-868.
- doi: 10.3350/cmh.2022.0434
The current requirement for biomarkers to detect hepatitis B virus (HBV) infection is polarized. One is a fully-automated and highly sensitive measurement system; the other is a simple system for... -
- CITED
-
- Close
- SHARE
-
- Close
- Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study
-
Nguyen VH, Le I, Ha A, Le RH, Rouillard NA, Fong A, Gudapati S, Park JE, Maeda M, Barnett S, Cheung R, Nguyen MH
- KMID: 2546387
- Clin Mol Hepatol.
- 2023 Oct;29(4):1002-1012.
- doi: 10.3350/cmh.2023.0205
Background/Aims: Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
-
Hsu YC, Tseng CH, Kao JH
- KMID: 2546375
- Clin Mol Hepatol.
- 2023 Oct;29(4):869-890.
- doi: 10.3350/cmh.2022.0420
Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set... -
- CITED
-
- Close
- SHARE
-
- Close
- The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
-
Chan LL, Chan SL
- KMID: 2546377
- Clin Mol Hepatol.
- 2023 Oct;29(4):909-923.
- doi: 10.3350/cmh.2023.0114
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the... -
- CITED
-
- Close
- SHARE
-
- Close
- Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
-
Byun HK, Kim C, Seong J
- KMID: 2546379
- Clin Mol Hepatol.
- 2023 Oct;29(4):945-957.
- doi: 10.3350/cmh.2023.0217
Hepatocellular carcinoma (HCC) is a highly lethal cancer with limited treatment options and poor prognosis. Carbon ion radiotherapy (CIRT) has emerged as a promising treatment modality for HCC due to... -
- CITED
-
- Close
- SHARE
-
- Close
- Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
-
Kim HI, An J, Han S, Shim JH
- KMID: 2546388
- Clin Mol Hepatol.
- 2023 Oct;29(4):1013-1028.
- doi: 10.3350/cmh.2023.0131
Background/Aims: There is no clear consensus on the relative ranking of interventional and radiation techniques with indications similar to those of radiofrequency ablation (RFA) for the treatment of early hepatocellular... -
- CITED
-
- Close
- SHARE
-
- Close
- Evidence-based hyponatremia management in liver disease
-
Ryu JY, Baek SH, Kim S
- KMID: 2546378
- Clin Mol Hepatol.
- 2023 Oct;29(4):924-944.
- doi: 10.3350/cmh.2023.0090
Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this... -
- CITED
-
- Close
- SHARE
-
- Close
